$13.170
-0.637 (-4.84%)收盤時
AGMB 資訊
AGMB 事件
Agomab Therapeutics NV Trading Halted Due to Volatility Trading Pause
Agomab Therapeutics NV trading halted, volatility trading pause
Agomab Initiates Phase 2b NOV-ERA Study for FSCD Treatment
Agomab announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal-restricted small molecule inhibitor of ALK5 for the potential treatment of Fibrostenosing Crohn's Disease, or FSCD. The company has aligned with the FDA on the study design of NOV-ERA, including the study's primary efficacy endpoint of endoscopic passability at Week 24 as assessed by the SES-CD narrowing score, as well as several secondary efficacy endpoints relevant to patients with FSCD. The protocol has been submitted to the FDA and has cleared central Institutional Review Board approval in the U.S. In addition, the study has received approval by Health Canada. The company has also submitted Clinical Trial Applications in multiple countries globally, including in the European Union and Asia Pacific territories. The company expects to initiate the NOV-ERA study following receipt of applicable regulatory and ethics approvals and plans to dose the first participants in the second half of 2026. The planned NOV-ERA study is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2b trial to assess the efficacy and safety of ontunisertib in participants diagnosed with symptomatic FSCD. The trial is expected to enroll up to 320 adult patients globally. To be eligible for the trial, participants must have at least one naive or anastomotic endoscopically non-passable ileal stricture, confirmed by a centrally read Simple Endoscopic Score for Crohn's Disease. Upon study initiation, participants will be randomized in a 1:1:1:1 ratio to receive either ontunisertib at one of three dose levels, or a matching placebo, administered twice daily. The trial will consist of a 6-week screening period, a 52-week treatment period, and a 2-week follow-up period.
Agomab Granted U.S. Patent for AGMB-447
Agomab announced that the United States Patent and Trademark Office, or USPTO, has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company's investigational inhaled lung-restricted small molecule inhibitor of ALK5, currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis. This patent provides intellectual property protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions.
Generate Biomedicines Debuts with 6% Price Increase
Generate Biomedicines made its public debut last week. The clinical‑stage company, which positions itself as a pioneer in AI‑driven drug design and development, enters the market with a pitch that its generative biology platform can accelerate and broaden therapeutic discovery.LATEST IPOS AND DIRECT LISTINGS:Generate Biomedicinesopened on February 27 at $15.00. The company priced 25M shares at $16.00. The deal priced at the midpoint of the $15.00-$17.00 target range. Generate Biomedicines is a clinical-stage generative biology company that says it is "pioneering the AI revolution in biotechnology and drug design and development."RECENT SPAC IPOS:Fortress Value Acquisition Vopened on February 26 at $10, after it priced its initial public offering of 25M Class A ordinary shares at a price of $10.00 per share.APEX Tech Acquisitionopened on February 26 at $9.98, after it priced its initial public offering of 10M units at an offering price of $10.00 per unit, with each unit consisting of one ordinary share and one right to receive one-fourth of one ordinary share upon the consummation of an initial business combination.MOZAYYX Acquisitionopened on February 25 at $9.96, after it priced its upsized initial public offering of 26.1M units at $10.00 per unit.ClearThink 1 Acquisitionopened on February 24 at $9.95, after it priced its initial public offering of 12.5M units at $10.00 per unit.PERFORMANCE:Price as of 11:00 am ET on Monday, March 2 -Generate Biomedicines – up over 6% at $13.48.RECENT IPOS TO WATCH:Forgent Power Solutions, Eikon Therapeutics, Bob's Discount Furniture, and Veradermicsare already seeing coverage roll out, while SpyGlass Pharma, Agomaband Once Upon A Farmare among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include Liftoff, Cerebras Systems, ayPay, and OpenAI.Clickto see upcoming IPO calendar on TipRanks.Liftoff Mobile- The company announced that it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The total number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process.Cerebras Systems– The company has filed confidentially for a U.S. initial public offering, The Information's Valida Pau and Katie Roof. The re-filing comes after a major sales pact with OpenAI, the authors note.PayPay Corporation- The company filed for an initial public offering of American depositary shares, or ADSs, and has applied to list the ADSs on the Nasdaq Global Select Market under the symbol "PAYP." The prospects filed with the SEC states, "As Japan's leading financial technology company, we are dedicated to our goal of becoming a digital finance platform for all... We launched this service in October 2018 and it rapidly expanded to become a nation-wide leading cashless payments ecosystem that had approximately 72 million PayPay registered users as of December 31, 2025, representing a penetration of 75% among 96 million smartphone users in Japan. With the acquisition of PayPay Card Corporation in October 2022, our platform evolved to a next-generation payments ecosystem, seamlessly integrating our code-based payment and credit card payment services through our PayPay app."OpenAI- The company is accelerating its plans for a public listing as rivalry with Anthropic intensifies, now planning on listing in Q4 of this year, Berber Jin, Corrie Driebusch, and Kate Clark of The Wall Street Journal. OpenAI is holding discussions with Wall Street banks about a potential initial public offering and has hired several executives to oversee its finance team, sources told the Journal.SpaceX- Elon Musk is targeting mid-June for the timing of SpaceX's initial public offering, IPO, Ivan Levingston, Stephen Morris, and Mercedes Ruehl of The Financial Times, citing five people familiar with the matter. The company is looking to raise $50B at a valuation of $1.5T, the sources added.Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
SpyGlass Pharma Surges Over 60% on First Trading Day
SpyGlass Pharma surged in its first day of trading at the end of last week, jumping more than 60% after pricing its initial public offering at $16, marking one of the strongest U.S. biotech debuts of the year and signaling renewed investor appetite for ophthalmology focused drug developers.LATEST IPOS AND DIRECT LISTINGS:Once Upon a Farmopened on February 6 at $21. The company had priced 10.997M shares, 7,631,537 shares of which were offered by Once Upon a Farm and 3,365,672 shares by certain existing stockholders, at $18.00, the midpoint of the $17.00-$19.00 target range. Once Upon a Farm, an organic food brand co-founded by actress Jennifer Garner, says its mission is to provide "organic, crave-worthy, snacks and meals for children of all ages."Agomabopened on February 6 at $14.70. The company had priced 12.5M shares at $16.00, inside the $15.00-$17.00 target range. Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need.SpyGlass Pharmaopened on February 6 at $24.00. The company had priced 9.375M shares $16.00, the midpoint of the $15.00-$17.00 range. SpyGlass Pharma is a late-stage biopharmaceutical company whose drug delivery technology is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.Forgent Power Solutionsopened on February 5 at $26. The company priced 56M shares at $27.00, at the midpoint of the $25.00-$29.00 target range. Forgent is a designer and manufacturer of electrical distribution equipment used in data centers, the power grid and energy-intensive industrial facilities.Eikon Therapeuticsopened on February 5 at $17.05. The company priced 21.18M shares at $18.00. The deal size was increased from 17.65M and priced at the top end of the $16.00-$18.00 range. Eikon is a late-stage clinical biopharmaceutical company whose initial focus is oncology, where it says it is advancing a pipeline of drug candidates "targeting areas of high unmet need in large indications" for various cancers.Bob's Discount Furnitureopened on February 5 at $17.00. The firm priced 19.45M shares at $17.00, the low end of the $17.00-$19.00 target range. Bob's is a national omnichannel retailer of value home furnishings with more than 200 showrooms across the United States.Veradermicsopened on February 4 at $34. The company had priced 15.08M shares at $17.00. The deal size was increased from 13.35M and priced above the $14.00-$16.00 range. Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing therapeutics for common aesthetic and dermatological conditions. Its lead program, VDPHL01, is being developed as an oral, non-hormonal treatment for men and women with pattern hair loss.RECENT SPAC IPOS:Hennessy Capital Investment VIIIopened on February 5 at $10.02. Although the blank check company reserves the right to pursue an acquisition opportunity in any business or industry, the company intends to focus its search for a target business in the industrial innovation and energy transition sectors.Cantor Equity Partners VIopened at $10.13. The blank check company's efforts to identify a prospective target business will not be limited to a particular industry or geographic region, but the company intends to focus on a target in an industry where it believes the company's management teams' and affiliates' expertise will provide the company with a competitive advantage, including the financial services, digital assets, healthcare, real estate services, technology and software industries.Iris Acquisition IIopened on February 3 at $9.96. Cohen & Company Capital Markets is acting as sole book-running manager for the offering.PERFORMANCE:Prices as of 11.00 am ET on Monday, February 9Once Upon a Farm – up over 15% at $24.26;Agomab – up more than 7% at $15.69;SpyGlass Pharma – fractionally down at $26.25;Forgent Power Solutions – up over 5% at $34.81;Eikon Therapeutics – up almost 4% at $15.02;Bob's Discount Furniture – up about 9% at $17.91;Veradermics – down almost 2% at $37.78.UPCOMING IPOS:Upcoming IPO and direct listings expected include OpenAI, AGI Inc, Speed Group, and Lendbuzz.Clickto see upcoming IPO calendar on TipRanks.OpenAIis accelerating its plans for a public listing as rivalry with Anthropic intensifies, now planning on listing in Q4 of this year, Berber Jin, Corrie Driebusch, and Kate Clark of The Wall Street Journal. OpenAI is holding discussions with Wall Street banks about a potential initial public offering and has hired several executives to oversee its finance team, sources told the Journal.AGI Inc, or Agibank,has filed with the SEC for an initial public offering of its Class A common shares. The company intends to apply to list its Class A common shares on the New York Stock Exchange under the symbol "AGBK." The prospectus states, "Agibank Brazil is a privately held financial holding company and the holder of 100% of the outstanding share capital of Banco Agibank S.A., or Banco Agibank. In turn, Nuova Holding S.A., or Nuova, was a privately held, non-financial holding company controlled by our controlling shareholder, Mr. Marciano Testa... Our mission is to revolutionize financial services for the largest and fastest growing segment of Brazil's population: individuals who have been underserved by incumbent banks and have not been effectively reached by digital-only banks. We seek to make credit and banking solutions more accessible and affordable for the Brazilian consumers who we believe need it the most, including social security beneficiaries and private and public sector workers."Speed Groupfiled a prospectus for 2.5M share initial public offering. It expects the IPO price to be in the range of $4.00 to $5.00 per. The company's operating subsidiary, Speed Logistics, is an e-commerce logistics provider providing end-to-end logistics solution in Hong Kong, Europe and North America. The services include warehousing, customs clearance, air transportation, and final delivery from the European airports. For the years ended June 30, 2024 and 2025, Speed's revenues were $17.9M and $22.64M, respectively.Lendbuzz Inc.is offering an undetermined number of shares of its common stock and the selling stockholders identified in this prospectus are offering additional shares of common stock, according to an initial public offering prospectus filed with the SEC. The company has applied to list its common stock on the Nasdaq Global Select Market under the symbol "LBZZ." The prospectus states: "Our mission is to offer fair access to credit for underserved populations. We are a financial technology company that utilizes artificial intelligence, or AI, and machine learning algorithms to better assess consumer credit risk and expand access to credit. We seamlessly process large sets of data through advanced computational approaches to more accurately predict a consumer's creditworthiness. Our business benefits both consumers through expanded access to credit, and auto dealerships via increased vehicle sales."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。







